Application note: Human iPS cells modified with Edit-R™ CRISPR-Cas9 reagents
Posted: 8 September 2020 | Horizon Discovery | No comments yet
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
Induced pluripotent stem cells are a valuable research tool for their ability to be turned into virtually any cell type. With the advent of CRISPR-Cas9 researchers can modify the genome of the iPS cells and subsequently differentiate them to see the affect that the genomic modification has upon the differentiated cell type. Here we present the ability to modify the genome and modulate expression of genes within a human induced pluripotent stem (iPS) cell line with Dharmacon™ Edit-R CRISPR reagents.
Related content from this organisation
- Targeting phosphodiesterase 3A: discovery of a promising cancer therapy
- Screening for COVID-19 drugs
- Assessing compound activity to accelerate drug discovery
- Why some screening hits are a PAIN
- Application note: Effectiveness of CRISPR‑Cas9 using pools of synthetic crRNAs in high-content analysis screening experiments
Related topics
Bioengineering, Biomarkers, Biopharmaceuticals, Cell culture, Disease research, Genome editing, Hit-to-Lead, Immunology, Personalised Medicine, Regenerative Medicine, Screening, Targets
Related organisations
Horizon Discovery
